Updated from 4:28 a.m. EST

BASEL, Switzerland ( TheStreet) -- Novartis ( NVS) said fourth-quarter earnings fell 2% despite a 10% increase in revenue.

Novartis, the Swiss drugmaker, earned $2.265 billion in the quarter, down from $2.323 billion a year earlier. Net sales in the quarter rose to $14.2 billion from $12.93 billion. Pharmaceutical sales rose 3% to $8 billion.

Novartis said sales in its vaccine division fell 74% to $361 million, impacting fourth-quarter profits. A year earlier the company saw $1 billion of pandemic flu vaccine sales which weren't repeated in the latest quarter.

In 2011, Novartis said reported sales growth would be lower "as a result of the combined effect of price reductions seen in 2010, the full impact of health care reform in the U.S. and generic competition."

-- Written by Joseph Woelfel

>To contact the writer of this article, click here: Joseph Woelfel

>To submit a news tip, send an email to: tips@thestreet.com.

If you liked this article you might like

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Novartis May Sell U.S. Generic Pill Business Amid Industry Struggles

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Teva Shares Fall as FDA OKs Another Generic Version of Multiple Sclerosis Drug

Axovant Shares Crater as CEO and President Both Resign

Axovant Shares Crater as CEO and President Both Resign

Generic Drug Makers Hurt By Latest Federal Government Budget

Generic Drug Makers Hurt By Latest Federal Government Budget